• 1
    DiMatteo MR. Variations in patients' adherence to medical recommendations – a quantitative review of 50 years of research. Med Care. 2004;42:200209.
  • 2
    Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J. 2008;336:11141117.
  • 3
    Hill MN, Miller NH, DeGeest S, American Socociety of Hypertension Writing Group. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12:757764.
  • 4
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes – a meta-analysis. Med Care. 2002;40:794811.
  • 5
    Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:15981605.
  • 6
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 7
    Fagard RH, Van den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002;20:12971302.
  • 8
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 9
    Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum – current outcomes and control in the community. JAMA. 2005;294:466472.
  • 10
    Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncontrolled systolic blood pressure among treated hypertensive patients in primary care in Belgium: results of the I-inSYST survey. J Hypertens. 2008;26:10572063.
  • 11
    Rose AJ, Glickman ME, D'Amore MM, et al. Effects of daily adherence to antihypertensive medication on blood pressure control. J Clin Hypertens (Greenwich). 2011;13:416421.
  • 12
    Shelley D, Tseng TY, Andrews H, et al. Predictors of blood pressure control among hypertensives in community health centers. Am J Hypertens. 2011;24:13181323.
  • 13
    Morris AB, Li JJ, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483492.
  • 14
    World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization: Geneva, Switzerland; 2003.
  • 15
    Abraham I, MacDonald K, Hermans C, et al. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vasc Health Risk Manag. 2011;7:209235.
  • 16
    Villa L, Abraham I, Macdonald K, Denhaerynck K. Correlation of physician-rated adherence with therapeutical outcomes in antihypertensive treatment: pooled analysis findings from six valsartan studies including 15,583 available patients. Value Health. 2011;14:A383A384.
  • 17
    Dobbels F, Berben L, De Simone S, et al. The psychometric properties and practicability of self-report instruments to identify medication non-adherence in adult transplant patients: a systematic review. Transplantation. 2010;90:205219.
  • 18
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:6774.
  • 19
    Twisk JWR. Applied Multilevel Analysis. Cambridge: University Press; 2006.
  • 20
    Kreft I, De Leeuw J. Introducing Multilevel Modeling. Thousand Oaks, CA: Sage; 2002.
  • 21
    Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;Art. No.: CD000011.
  • 22
    Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc. 2009;49:164170.
  • 23
    Gutierrez-Angulo ML, Lopetegi-Uranga P, Sanchez-Martin I, Garaigordobil-Landazabal M. [Therapeutic compliance in patients with arterial hypertension and type 2 diabetes mellitus]. Rev Calid Asist. 2012;27:7277.
  • 24
    Stults B, Jones R. Management of hypertension in diabetes. Diabetes Spectr. 2006;19:2531.
  • 25
    Verpooten GA, Aerts A, Coen N, et al. Antihypertensive effectiveness of aliskiren for the ‘real-world’ management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract. 2011;65:5463.
  • 26
    Choudhry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. Ann Intern Med. 2005;142:260273.
  • 27
    Gouni-Berthold I, Berthold HK. Role of physician gender in drug therapy. Handb Exp Pharmacol. 2012;214:183208.
  • 28
    Scheen AJ, Philips JC, Krzesinski JM. [Hypertension and diabetes: about a common but complex association]. Rev Med Liege. 2012;67:133138.
  • 29
    Ruckert IM, Schunk M, Holle R, et al. Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies. Cardiovasc Diabetol. 2012;11:50.
  • 30
    Sakurai M, Stamler J, Miura K, et al. Relationship of dietary cholesterol to blood pressure: the INTERMAP study. J Hypertens. 2011;29:222228.
  • 31
    de Simone G, Devereux RB, Chinali M, et al. Risk factors for arterial hypertension in adults with initial optimal blood pressure – the strong heart study. Hypertension. 2006;47:162167.
  • 32
    Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs. 2009;9:309330.